{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:17:38Z","timestamp":1747196258827,"version":"3.40.5"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"International Medical University in Malaysia","award":["BMS 1\/2019 (007))."],"award-info":[{"award-number":["BMS 1\/2019 (007))."]}]},{"name":"International Medical University in Malaysia","award":["BMS 1\/2019 (007)"],"award-info":[{"award-number":["BMS 1\/2019 (007)"]}]},{"name":"International Medical University in Malaysia","award":["BMS 1\/2019 (007)"],"award-info":[{"award-number":["BMS 1\/2019 (007)"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Gastric cancer is one of the most common malignancies around the world, and a variety of neoadjuvant chemotherapies with different drug combinations are available for the treatment. R0 resection refers to a microscopically negative margin on resection, where no gross or microscopic tumour remains in the primary tumour. We aimed to find evidence on the relative effectiveness of neoadjuvant therapies for patients with advanced gastroesophageal and gastric cancer on the R0 resection rate.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Relevant randomised controlled trials were searched using appropriate keywords in health-related databases. We performed network meta-analysis within a frequentist framework. The endpoint assessed was the R0 resection rate. We assessed consistency and transitivity assumptions that are necessary for network meta-analysis. This study only used data from published studies. The need for consent from participants was waived by the Ethics Review Committee of the International Medical University in Malaysia.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Six randomised controlled trials involving 1700 patients were identified. A network plot was formed with five neoadjuvant regimens [DLX (pyrimidine analogue + platinum compounds + chemoradiotherapy), DELX (pyrimidine analogue + epipodophylllotoxins\/etoposide + platinum compounds + chemoradiotherapy), ADL (anthracycline + pyrimidine analogue + platinum compounds), ADM (anthracycline+ pyrimidine analogue + anti-folate compounds) and LTX (platinum compounds + taxane + chemoradiotherapy)] and surgery alone for management of patients with advanced gastroesophageal and gastric cancer. Assumptions required for a network meta-analysis such as consistency ((global test: <jats:italic>Chi<\/jats:italic><jats:sup>2<\/jats:sup> (1): 3.71; <jats:italic>p<\/jats:italic>:0.054)), and the transitivity in accord to the characteristics of interventions considered in this review were not violated. In the network comparison, surgery alone has a lower R0 resection rate compared with LTX (OR 0.2, 95%CI:0.01, 0.38) or DLX (OR 0.48, 95%CI: 0.29, 0.79). LTX has higher resection rate compared with DLX (OR 2.47, 95%CI: 1.08 to 5.63), DELX (OR 106.0, 95%CI: 25.29 to 444.21), ADM (OR 5.41, 95%CI: 1.56 to 18.78) or ADL (OR 3.12, 95%CI: 1.27 to 7.67). There were wide or very wide CIs in many of these comparisons. Overall certainty of the evidence was low or very low. Further research in this field is very likely to have an important impact on our confidence in the R0 resection rates between LTX versus other neoadjuvant chemotherapy is likely to change the estimate.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Findings suggest that overall quality of evidence on the relative effectiveness of neoadjuvant chemotherapies was low to very low level. Therefore, we are very uncertain about the true effect of neoadjuvant therapies in the R0 resection rate in patients with gastroesophageal and gastric cancer. Future well-designed large trials are needed. To recruit large samples in this field, multicountry trials are recommended. Future trials also need to assess treatment-related adverse events, and patients-centered outcomes such as health\u2010related quality of life.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0275186","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T17:37:52Z","timestamp":1664213872000},"page":"e0275186","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["A comparison of neoadjuvant therapies for gastroesophageal and gastric cancer on tumour resection rate: A network meta-analysis"],"prefix":"10.1371","volume":"17","author":[{"given":"Seow Chee","family":"Herng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-8629","authenticated-orcid":true,"given":"Norah Htet","family":"Htet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-7149","authenticated-orcid":true,"given":"Cho","family":"Naing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"pone.0275186.ref001","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015. A systematic analysis for the global burden of disease study","volume":"3","author":"C Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"journal-title":"GLOBOCAN","year":"2021","author":"WHO","key":"pone.0275186.ref002"},{"key":"pone.0275186.ref003","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11894-017-0575-8","article-title":"Changing trends in stomach cancer throughout the world","volume":"19","author":"M Balakrishnan","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"pone.0275186.ref004","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"pone.0275186.ref005","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4103\/0973-1482.29830","article-title":"Pathogenesis and treatment of gastric carcinoma: An update with brief review","volume":"2","author":"FA Khan","year":"2006","journal-title":"J Can Res Ther"},{"issue":"5","key":"pone.0275186.ref006","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Clinical practice guidelines","volume":"27","author":"EC Smyth","year":"2016","journal-title":"Annals of Oncology"},{"key":"pone.0275186.ref007","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/MAJ.0000000000000476","article-title":"Concurrent neoadjuvant chemoradiotherapy for Siewert II and III adenocarcinoma at gastroesophageal junction","volume":"349","author":"Q Zhao","year":"2015","journal-title":"Am J Med Sci"},{"article-title":"Clinical features, diagnosis, and staging of gastric cancer","year":"2020","author":"PF Mansfield","key":"pone.0275186.ref008"},{"key":"pone.0275186.ref009","doi-asserted-by":"crossref","first-page":"7384","DOI":"10.3748\/wjg.v18.i48.7384","article-title":"Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric\/gastroesophageal cancer: a meta-analysis","volume":"18","author":"L Ge","year":"2012","journal-title":"World J Gastroenterol"},{"key":"pone.0275186.ref010","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.3748\/wjg.v16.i44.5621","article-title":"Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis","volume":"16","author":"W Li","year":"2010","journal-title":"World J Gastroenterol"},{"key":"pone.0275186.ref011","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO.2001.19.12.3058","article-title":"Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging","volume":"19","author":"WA Weber","year":"2001","journal-title":"J Clin Oncol"},{"key":"pone.0275186.ref012","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for oesophageal or junctional cancer","volume":"366","author":"P Van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"pone.0275186.ref013","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2009.26.6114","article-title":"Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954","volume":"28","author":"C Schuhmacher","year":"2010","journal-title":"J Clin Oncol"},{"key":"pone.0275186.ref014","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ejso.2004.04.013","article-title":"Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial","volume":"30","author":"HH Hartgrink","year":"2004","journal-title":"Eur J Surg Oncol"},{"key":"pone.0275186.ref015","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.3748\/wjg.v16.i27.3358","article-title":"R0 resection in the treatment of gastric cancer: room for improvement","volume":"16","author":"A Biondi","year":"2010","journal-title":"World J Gastroenterol"},{"key":"pone.0275186.ref016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0344-0338(11)80700-4","article-title":"The pathologist and the residual tumor (R) classification","volume":"190","author":"P Hermanek","year":"1994","journal-title":"Pathol Res Pract"},{"key":"pone.0275186.ref017","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3748\/wjg.v24.i2.274","article-title":"Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?","volume":"24","author":"R Reddavid","year":"2018","journal-title":"World J Gastroenterol"},{"key":"pone.0275186.ref018","doi-asserted-by":"crossref","first-page":"704244","DOI":"10.3389\/fonc.2021.704244","article-title":"safety and efficacy of laparoscopic versus open gastrectomy in patients with advanced gastric cancer following neoadjuvant chemotherapy: a meta-analysis","volume":"11","author":"XL Liao","year":"2021","journal-title":"Front Oncol"},{"key":"pone.0275186.ref019","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12885-018-4027-0","article-title":"Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis","volume":"18","author":"ZF Miao","year":"2018","journal-title":"BMC Cancer"},{"key":"pone.0275186.ref020","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ags3.12444","article-title":"Clinical TNM staging for esophageal, gastric, and colorectal cancers in the era of neoadjuvant therapy: A systematic review of the literature","volume":"5","author":"H Shimada","year":"2021","journal-title":"Ann Gastroenterol Surg"},{"key":"pone.0275186.ref021","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2288-11-61","article-title":"Network meta-analysis of survival data with fractional polynomials","volume":"11","author":"JP Jansen","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"pone.0275186.ref022","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"mixed-treatment comparison, network, or multiple treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti G. Indirect","year":"2012","journal-title":"Res Synth Methods"},{"key":"pone.0275186.ref023","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations","volume":"162","author":"B Hutton","year":"2015","journal-title":"Ann Intern Med"},{"volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","year":"2021","author":"JPT Higgins","key":"pone.0275186.ref024"},{"key":"pone.0275186.ref025","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"GH Guyatt","year":"2008","journal-title":"BMJ"},{"key":"pone.0275186.ref026","doi-asserted-by":"crossref","DOI":"10.1002\/9780470743386","volume-title":"An Introduction to Meta-Analysis","author":"M Borenstein","year":"2009"},{"volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.3","year":"2022","author":"JJ Deeks","key":"pone.0275186.ref027"},{"key":"pone.0275186.ref028","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"A Chaimani","year":"2013","journal-title":"PloS One"},{"key":"pone.0275186.ref029","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta\u2010analysis: model estimation using multivariate meta\u2010regression","volume":"3","author":"IR White","year":"2012","journal-title":"Res Syn Meth"},{"key":"pone.0275186.ref030","first-page":"1185","article-title":"Multivariate random-effects meta-analysis","volume":"15","author":"IR White","year":"2015","journal-title":"Stata Journal"},{"key":"pone.0275186.ref031","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"JP Higgins","year":"2012","journal-title":"Res Synth Methods"},{"volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (","year":"2022","author":"A Chaimani","key":"pone.0275186.ref032"},{"key":"pone.0275186.ref033","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/eb-2017-102753","article-title":"Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article","volume":"20","author":"A Chaimani","year":"2017","journal-title":"Evid Based Ment Health"},{"key":"pone.0275186.ref034","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"G Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"pone.0275186.ref035","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence.","volume":"64","author":"H Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"pone.0275186.ref036","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"GRADE Working Group. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"R Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"pone.0275186.ref037","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","volume":"64","author":"GH Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"pone.0275186.ref038","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"G Salanti","year":"2014","journal-title":"PloS ONE"},{"key":"pone.0275186.ref039","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open label, randomised phase 3 trial","volume":"19","author":"A Cats","year":"2018","journal-title":"Lancet Oncol"},{"key":"pone.0275186.ref040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2017.04.027","article-title":"Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial","volume":"81","author":"M Stahl","year":"2017","journal-title":"Eur J Cancer"},{"key":"pone.0275186.ref041","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial","volume":"29","author":"M Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"pone.0275186.ref042","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.intimp.2011.01.012","article-title":"Triptolide and its expanding multiple pharmacological functions","volume":"11","author":"Q Liu","year":"2011","journal-title":"International Immunopharmacology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0275186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T17:38:56Z","timestamp":1664213936000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0275186"}},"subtitle":[],"editor":[{"given":"Sandro","family":"Pasquali","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0275186","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,9,26]]}}}